🇺🇸 FDA
Patent

US 8377924

Protein kinase C inhibitors and uses thereof

granted A61KA61K31/506A61K31/5377

Quick answer

US patent 8377924 (Protein kinase C inhibitors and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/506, A61K31/5377, A61K31/538, A61K31/55